Novel agent shows promise in treating the most aggressive type of breast cancer
A global clinical study confirms the effectiveness of targeted antibody drug conjugates against refractory metastatic triple-negative breast cancer
2021-04-22
(Press-News.org) BOSTON - A unique antibody drug conjugate (ADC), which delivers a high dose of a cancer-killing drug to tumor cells through a targeted antibody, has been found in a global phase 3 clinical study to nearly double the survival time of patients with refractory metastatic triple-negative breast cancer. The study of the ADC drug sacituzumab govitecan (SG), for which Massachusetts General Hospital (MGH) was a lead clinical research site after serving as the lead site for the pivotal phase 1/2 trial, reported superior outcomes compared to single-agent chemotherapy, the standard for treating metastatic triple-negative breast cancer. The phase 3 results of the study, known as ASCENT, were published in the New England Journal of Medicine.
"Favorable results with SG versus chemotherapy were observed in terms of progression-free survival (the length of time the cancer was kept from spreading); the amount of time between the start of treatment and cancer progression; and overall survival--the length of time before death from any cause," says global principal investigator Aditya Bardia, MD, MPH, an attending physician in the Department of Medical Oncology at Mass General Cancer Center. "These statistically significant findings give patients with this devastating disease new cause for hope. We need to build on that progress and accelerate further development of antibody drug conjugates and combination therapies for patients with breast cancer."
Metastatic triple-negative breast cancer is the most aggressive type of breast cancer with a poor prognosis. Chemotherapy has remained the only standard treatment option, but it is associated with low response rates and short progression-free survival. SG, which was developed and is manufactured by Immunomedics, a subsidiary of Gilead Sciences, received accelerated approval by the U.S. Food and Drug Administration in April 2020 on the basis of favorable phase 1/2 clinical trials, with full approval contingent on the confirmatory phase 3 results.
ASCENT is a global study to evaluate the safety and efficacy of the antibody drug conjugate compared to chemotherapy in 529 patients with metastatic triple-negative breast cancer whose cancer had relapsed or was resistant to at least two other forms of therapy. The investigators found that median progression-free survival with the ADC agent was 5.6 months compared to 1.7 months with chemotherapy, and that median overall survival was 12.1 months with the ADC agent compared to 6.7 months with chemotherapy. The study also found that the response rate-- that is, shrinkage in the size of the metastatic tumor sites--was 35% after administration of ADC compared to 5% with chemotherapy.
ADCs are complex molecules that combine the targeting capabilities of monoclonal antibodies with the cancer-killing strength of cytotoxic drugs. In the case of sacituzumab govitecan, the monoclonal antibody seeks out the antigen (or protein), known as Trop-2 that is overexpressed on the surface of tumor cells, and delivers the anti-cancer drug SN-38 in a highly concentrated dose that destroys cancerous cells while sparing normal ones. ADCs have been established as a treatment option for HER2-positive breast cancer.
"We believe antibody drug conjugates are particularly promising as building blocks for effective new combination treatments," says Bardia. "The goal is to not only improve patient outcomes, but also to establish ADCs as first-line therapy or even earlier so that these powerful agents can play a role in preventing the spread of triple-negative breast cancer."
INFORMATION:
Bardia is director of the breast cancer research program at Mass General Cancer Center and assistant professor of Medicine at Harvard Medical School.
The study was supported by Immunomedics, a subsidiary of Gilead Sciences, Inc.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America's Best Hospitals."
ELSE PRESS RELEASES FROM THIS DATE:
2021-04-22
A new study has found up to half of all children with language difficulties and mental and physical health problems have been exposed to intimate partner violence, prompting calls for health and social care services to provide more effective identification and early intervention.
The research, led by the Murdoch Children's Research Institute (MCRI) and published in The BMJ, showed children exposed to intimate partner violence from infancy were twice as likely to have a psychiatric diagnosis, emotional and behavioural difficulties, and impaired language skills at age 10. They were also more likely to have asthma and sleep problems.
The study also found that ...
2021-04-21
MINNEAPOLIS - Intracerebral hemorrhage is a life-threatening type of stroke caused by bleeding within the brain tissue. Survivors are at high risk of having another bleeding stroke. Most of these strokes are caused by changes in the narrowest blood vessels in the brain, a condition known as cerebral small vessel disease. A new study has found that differences in the extent of one type of cerebral small vessel disease may contribute to differences in people's risk for a second bleeding stroke. The research is published in the April 21, 2021, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Cerebral small vessel disease is an umbrella term for a number of conditions that involve changes in the smallest blood vessels in the ...
2021-04-21
MINNEAPOLIS - Women who have migraine before menopause may have an increased risk of developing high blood pressure after menopause, according to a study published in the April 21, 2021, online issue of Neurology®, the medical journal of the American Academy of Neurology.
"Migraine is a debilitating disorder, often resulting in multiple severe headaches a month, and typically experienced more often by women than men," said study author Gianluca Severi, Ph.D. of the French National Institute of Health and Medical Research in Paris. "Migraine is most prevalent in women in the years before menopause. After ...
2021-04-21
HERSHEY, Pa. -- Next time you make a salad, you might want to consider adding mushrooms to it. That's because higher mushroom consumption is associated with a lower risk of cancer, according to a new Penn State study, published on March 16 in Advances in Nutrition.
The systematic review and meta-analysis examined 17 cancer studies published from 1966 to 2020. Analyzing data from more than 19,500 cancer patients, researchers explored the relationship between mushroom consumption and cancer risk.
Mushrooms are rich in vitamins, nutrients and antioxidants. The team's findings show that these super foods may also help guard against cancer. Even though shiitake, oyster, ...
2021-04-21
DURHAM, N.C. -- When marine biologist Eleanor Caves of the University of Exeter thinks back to her first scuba dives, one of the first things she recalls noticing is that colors seem off underwater. The vivid reds, oranges, purples and yellows she was used to seeing in the sunlit waters near the surface look increasingly dim and drab with depth, and before long the whole ocean loses most of its rainbow leaving nothing but shades of blue.
"The thing that always got me about diving was what happens to people's faces and lips," said her former Ph.D. adviser Sönke Johnsen, a biology professor at Duke University. "Everybody has a ghastly sallow complexion."
Which got the researchers to thinking: In the last half-century, some fish have been shifting ...
2021-04-21
Researchers at GMI - Gregor Mendel Institute of Molecular Plant Biology of the Austrian Academy of Sciences - and the John Innes Centre, Norwich, United Kingdom, determine that gene-regulatory mechanisms at an early embryonic stage govern the flowering behavior of Arabidopsis later in development. The paper is published in the journal PNAS.
How do early life events shape the ability of organisms to respond to environmental cues later in their life? Can such phenomena be explained at the mechanistic level? GMI group leader and co-corresponding author Michael Nodine counters these questions with a clear statement: "Our research demonstrates that gene-regulatory mechanisms established in early embryos forecast events that have major ...
2021-04-21
UC Riverside engineers are developing methods to estimate the impact of California's destructive wildfires on air quality in neighborhoods affected by the smoke from these fires. Their research, funded by NASA and the results published in Atmospheric Pollution Research, fills in the gaps in current methods by providing air quality information at the neighborhood scales required by public health officials to make health assessments and evacuation recommendations.
Measurements of air quality depend largely on ground-based sensors that are typically spaced many miles apart. Determining how healthy it is to breathe air is straightforward in the vicinity of the sensors but becomes unreliable in areas in between sensors.
Akula Venkatram, a professor of mechanical engineering in UC Riverside's ...
2021-04-21
Much of common pharmaceutical development today is the product of laborious cycles of tweaking and optimization. In each drug, a carefully concocted formula of natural and synthetic enzymes and ingredients works together to catalyze a desired reaction. But in early development, much of the process is spent determining what quantities of each enzyme to use to ensure a reaction occurs at a specific speed.
New collaborative research from Northwestern University could expedite, or even eliminate, the need for scientists to manually adjust bioproduction reaction conditions at all. Using ideas conceived by graduate students across three labs, Northwestern researchers developed technology that allows microbes to produce drugs with feedback control systems, dialing down or amping up ...
2021-04-21
Cisgender sexual minority men and transgender women are aware of pre-exposure prophylaxis (PrEP), a daily pill for HIV-negative people to prevent HIV infection, but few are currently taking it, according to researchers at Rutgers.
The study, published in the journal AIDS and Behavior, surveyed 202 young sexual minority men and transgender women - two high-priority populations for HIV prevention - to better understand why some were more likely than others to be taking PrEP.
According to the Centers for Disease Control and Prevention, sexual minority men are the community most impacted by HIV, making ...
2021-04-21
Skoltech scientists in collaboration with researchers from the University of Arizona and the Los Alamos National Laboratory have developed an approach that allows power grids to return to stability fast after demand response perturbation. Their research at the crossroads of demand response, smart grids, and power grid control was published in the journal Applied Energy.
Power grids are complex systems that manage the generation, transmission and distribution of electrical power to consumers, also called loads. As it is not possible to store electrical energy along the transmission lines, grid operators must ensure, ideally at all times, the balance between production and consumption of electrical energy, i.e. the stability of power grids. While it is essential ...
LAST 30 PRESS RELEASES:
[Press-News.org] Novel agent shows promise in treating the most aggressive type of breast cancer
A global clinical study confirms the effectiveness of targeted antibody drug conjugates against refractory metastatic triple-negative breast cancer
